Clinical Pathologist II

About the role

Responsible for all aspects of clinical pathology conducted on research studies. Partner with Study Directors to provide comprehensive interpretation and preparation of the clinical pathology portions of reports. Participate in protocol development, measurement of hematology, coagulation, clinical chemistry, and urinalytical parameters.

Responsibilities

• Interpret clinical pathology data and prepare comprehensive clinical pathology reports.
• Aid Study Directors in the interpretation of clinical pathology endpoints.
• Serve as Study Clinical Pathologist or Principal Investigator on studies, including in situ hybridization and immunohistochemistry.
• Interact with Anatomic Pathologists to ensure relevant and appropriate correlations for clinical and anatomical pathology endpoints.
• Evaluate study specimens related to clinical pathology, such as blood smears, bone marrow smears, urinalysis sediment preparations, and body fluid preparations.
• Provide scientific expertise for experimental design and conduct of research studies.
• Participate in method development and identification and evaluation of new instrumentation.
• Assist in expanding the array of clinical pathology assays to meet contemporary needs and expectations.
• Assist in on-site employee training in clinical pathology or related topics.
• Provide expertise and guidance to Clinical Pathology personnel with technical issues.
• Review and approve new/revised Standard Operating Procedures (SOPs) pertaining to pathology.
• Interact and communicate with Sponsors to ensure good client relations.
• Participate on committees and in professional activities as deemed appropriate.

Requirements

• DVM/VMD (Doctor of Veterinary Medicine) degree or equivalent required; Ph.D. in Clinical Pathology or related discipline preferred.
• Minimum 3 years related experience in clinical pathology or experimental pathology with demonstrated research capability as shown by publications in peer-reviewed journals.
• Experience in the contract research or pharmaceutical industry with Postdoctoral experience or advanced/specialized education preferred.
• Board certification by the American College of Veterinary Pathologists (D.A.C.V.P.) Specialty in Clinical Pathology required.
• Full understanding of regulatory requirements, Good Laboratory Practices (GLPs), site SOPs, and study types assigned.
• Knowledge of applicable international guidelines for all types of toxicology studies.
• Demonstrate leadership skills for intra- and interdepartmental initiatives, Sponsor interactions, and business development.
• Effective written and verbal communication skills.
• Ability to handle multiple projects, prioritize work, and meet deadlines.
• Proficiency in standard software including Microsoft® Excel, Word, PowerPoint, and laboratory calculations and statistical interpretation.

This position is open to a Hybrid or Remote work schedule and will require some occasional travel.

Pay

The pay range for this position is $180,000 - $200,000. Salaries vary within the range based on factors including, but not limited to, experience, skills, education, certifications, and location.

About the company

Charles River is an early-stage contract research organization (CRO) committed to helping partners expedite preclinical drug development with exceptional safety assessment services, state-of-the-art facilities, and expert regulatory guidance. We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development.

With over 20,000 employees within 110 facilities in over 20 countries, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving unique client challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions around the world. Each year, approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities, and we have proudly worked on 80% of the drugs approved by the U.S. Food and Drug Administration (FDA) in the past five years.